Hypertonic saline/epinephrine treatment in hospitalized infants with viral bronchiolitis reduces hospitalization stay: 2 years experience

Israel Medical Association Journal

Volumn 8, Issue 3, 2006, Pages 169-173

  Tal, Guy ^a,b   Cesar, Karine ^a,b   Oron, Anat ^a,b   Houri, Sion ^a,b   Ballin, Ami ^a,b   Mandelberg, Avigdor ^a,b  

^a WOLFSON MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Epinephrine; Hypertonic saline; Inhalation; Respiratory syncytial virus; Viral bronchiolitis

Indexed keywords

ADRENALIN; SODIUM CHLORIDE;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HOSPITAL ADMISSION; HUMAN; INFANT; ISRAEL; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK REDUCTION; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL BRONCHIOLITIS; WINTER;

ADMINISTRATION, INHALATION; BRONCHIOLITIS, VIRAL; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; EPINEPHRINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LENGTH OF STAY; MALE; NEBULIZERS AND VAPORIZERS; RETROSPECTIVE STUDIES; SALINE SOLUTION, HYPERTONIC; TREATMENT OUTCOME;

EID: 33645469266     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344:1917-28.
2. Darville T, Yamauchi T. Respiratory syncytial virus. Pediatr Rev 1998;19:55-61.
3. Guerguerian A-M, Gauthier M, Lebel MH, Farrell CA, Lacroix J. Ribavirin in ventilated respiratory syncytial virus bronchiolitis: a randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999;160:829-34.
4. Wheeler JG, Wofford J, Turner RB. Historical cohort evaluation of ribavirin efficacy in respiratory syncytial virus infection. Pediatr Infect Dis J 1993;12:209-13.
5. Van Woensel JB, Wolfs TF, van Aalderen WM, Brand PL, Kimpen JL. Randomized double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis. Thorax 1997;52:634-7.
6. Cade A, Brownlee KG, Conway SP, et al. Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis. Arch Dis Child 2000;82:126-30.
7. Bertrand P, Aranibar H, Castro E, Sanchez I. Efficacy of nebulized epinephrine versus salbutamol in hospitalized infants with bronchiolitis. Pediatr Pulmonol 2001;31:284-8.
8. Patel H, Platt RW, Pekeles GS, Ducharme FM. A randomized, controlled trial of the effectiveness of nebulized therapy with epinephrine compared with albuterol and saline in infants hospitalized for acute viral bronchiolitis. J Pediatr 2002;141:818-24.
9. Wainwright C, Altamirano L, Cheney M, et al. A multicenter, randomized, double-blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis. N Engl J Med 2003;349:27-35.
10. Wills PJ, Hall RL, Chan W, Cole PJ. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J Clin Invest 1997;99:9-13.
11. Sood N, Bennett WD, Zeman K, et al. Increasing concentration of inhaled saline with or without amiloride: effect on mucociliary clearance in normal subjects. Am J Respir Crit Care Med 2003;167:158-63.
12. Mandelberg A, Tal G, Witzling M, et al. Nebulized 3% hypertonic saline treatment in hospitalized infants with viral bronchiolitis. Chest 2003;123:481-7.
13. O'Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax 1997;2(Suppl 2):S31-44.
14. Wang EEL, Milner RA, Navas L, Maj H. Observer agreement for respiratory signs and oximetry in infants hospitalized with lower respiratory infections. Am Rev Respir Dis 1992;145:106-9.
15. Sarrell EM, Tal G, Witzling M, et al. Nebulized 3% hypertonic saline treatment in ambulatory children with viral bronchiolitis decreases symptoms. Chest 2002;122:215-20.
16. Scheffer AL, Medler LW, Sarret HP. The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine. Am Rev Respir Dis 1964;90:721-9.
17. Dasgupta B, Tomkiewicz RP, Boyd WA, Brown NE, King M. Effects of combined treatment with rhDNase and airflow oscillations on spinnability of cystic fibrosis sputum in vitro. Pediatr Pulmonol 1995;20:78-82.
18. King M, Dasgupta B, Tomkiewicz RP, Brown NE. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease 1. Am J Respir Crit Care Med 1997;156:173-7.
19. Pavia D, Thomson ML, Clarke SW. Enhanced clearance of secretions from the human lung after the administration of hypertonic saline aerosol. Am Rev Respir Dis 1978;117:199-202.
20. Ciesla DI, Moore EE, Zallen G, Biffl WL, Silliman CC. Hypertonic saline attenuation of polymorphonuclear neutrophil cytotoxicity: timing is everything. J Trauma 2000;48:388-95.
21. Arbabi S, Garcia I, Bauer G, Maier RV. Hypertonic saline induces prostacyclin production via extracellular signal-regulated kinase (ERK) activation. J Surg Res 1999;83:141-6.
22. Popov M, Pizzichini M, Pizzichini E, et al. Some technical factors influencing the induction of sputum for cell analysis. Eur Respir J 1995;8:559-65.
23. Suri R, Marshall LJ, Wallis C, Metcalfe C, Bush A, Shute JK. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. Am J Respir Crit Care Med 2002;166:352-5.
24. Amirav I, Oron A, Tal G, et al. Aerosol delivery in respiratory syncytial virus bronchiolitis: hood or face-mask? J Pediatr 2005;147(5):627-31.
25. Wark PAB, McDonald V. Nebulised hypertonic saline for cystic fibrosis (Cochrane Review). In: The Cochrane Library, 2, 2001. Oxford: Update Software.